Treeline Biosciences (or Treeline) announced the initiation of Phase 1 trials for two internally discovered programs, TLN-121 and TLN-372, and a third in-licensed program, TLN-254. TLN-121, a BCL6 degrader, and TLN-254, an EZH2 inhibitor, are both being studied in patients with lymphoma. TLN-372, a pan-KRAS inhibitor, is being studied in patients with cancers expressing certain KRAS mutations. The company also announced the close of a $200 million Series A extension, bringing total funding to $1.1 billion.

Series A extension investors include: AI Life Sciences, an affiliate of Access Industries; ARCH Venture Partners; OrbiMed; GV; KKR; accounts advised by T. Rowe Price Associates, Inc.; Ajax Health/Zeus; Casdin Capital; Fidelity Management & Research Company; Aisling Capital; Rock Springs Capital; and Exor.